Core Insights - Nanobiotix announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) for lung cancer at the 2025 European Lung Cancer Conference [1] Group 1: Study Presentations - The first study focuses on reirradiation with NBTXR3 for inoperable locoregional recurrent non-small cell lung cancer (NSCLC) [2] - The second study evaluates NBTXR3 activated by stereotactic body radiotherapy (SBRT) in combination with immune checkpoint inhibitors for lung metastases from NSCLC or other solid tumors [3] Group 2: Product Overview - NBTXR3 is a novel oncology product made of functionalized hafnium oxide nanoparticles, administered via a one-time intratumoral injection and activated by radiotherapy [4] - The product aims to induce significant tumor cell death and trigger an adaptive immune response, potentially applicable across various solid tumors treated with radiotherapy [4] Group 3: Regulatory and Development Strategy - NBTXR3 is being evaluated in multiple solid tumor indications, including a global Phase 3 study in head and neck squamous cell cancers [5] - The FDA granted Fast Track designation for NBTXR3 activated by radiation therapy for patients with locally advanced head and neck squamous cell carcinoma [5] Group 4: Collaboration and Licensing - Nanobiotix has engaged in a collaboration with The University of Texas MD Anderson Cancer Center to expand the development of NBTXR3 [6] - In 2023, a license agreement for global co-development and commercialization of NBTXR3 was established with Janssen Pharmaceutica NV, a Johnson & Johnson company [7] Group 5: Company Background - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for patients [8] - The company was incorporated in 2003 and is headquartered in Paris, France, with listings on Euronext Paris and Nasdaq [9]